Skip to main content
Clinic CJC-1295

A Carbon-grid data console on the CJC-1295 literature — the DAC vs no-DAC pharmacokinetics, the early human studies, and the halted Phase 2 program, read straight from the record.

what people said / what studies did not test

What do CJC-1295 personal reports tell you?

They list what people noticed, but give no head count. Personal reports can't prove a cause. The separate safety facts come from named sources.

Published study resultsThe source list

How much can personal reports prove?

CJC-1295 personal reports list what users noticed. They mention sleep, soreness, body fat, energy, focus, skin, swelling, tingling, headache, hunger, and blood sugar. No total number of people was recorded. The reports also can't show whether the drug caused any claim.

Your safest reading keeps reports apart from study results. Repeated claims remain personal accounts. A study comparing treated and untreated people gives a fairer test. The next part lists accounts; the final part gives sourced safety facts.

What did people report during research use?

These accounts came from peptide forums, consumer summaries, and clinic guides. They describe what people said while using CJC-1295 for research, not what a controlled study found. The source notes gave no total number of people. The rankings below show only which claims recurred more in those sources.

Reports people welcomed

  • Deeper sleep ranked near the top. People described falling asleep sooner and waking less. Trials did not test sleep.
  • Less soreness ranked in the middle group. People linked quicker recovery after hard exercise to the drug. Better sleep and ordinary rest could cause the same result.
  • Less belly fat ranked in the middle group. These reports covered several weeks. Food and exercise were changing at the same time.
  • Easier muscle retention ranked in the middle group. People described looking leaner while dieting. Their food and exercise make the cause unclear.
  • Firmer skin and better-moving joints ranked lower. People were describing how their skin felt and how their joints moved. No controlled study measured either claim.
  • More daytime energy ranked lower. Other people noticed no added energy. Some credited better sleep.
  • Clearer thinking ranked lower. A smaller group described steadier focus. Those people also credited sleep.

Reports people disliked

  • Swelling and puffiness ranked near the top. Hands and faces felt puffy or heavy. Many reports named long-form DAC, the kind that joins a blood protein.
  • Shot-site redness or soreness ranked in the middle group. People also described itching or a small bump. The sore spot usually eased soon.
  • Tingling or numb hands ranked in the middle group. People compared it with carpal tunnel, which means pressure on a wrist nerve. They thought trapped fluid caused that pressure.
  • Higher blood sugar ranked lower. People checking their sugar saw higher numbers. These accounts were not study findings.
  • Tiredness or sleepiness ranked lower. Some people felt slow during the day. Their reports conflict with the claims of added energy.
  • Warmth or a head rush ranked lower. People described a flushed face or brief light-headed feeling. More reports named the short no-DAC form.
  • Headache ranked lower. The reported headaches were mild and brief. Many causes besides the drug were possible.
  • Hunger ranked lower. The source review said hunger mainly appeared with ipamorelin. Ipamorelin is a lab drug that acts like the body's hunger hormone. The people blamed that second drug more than CJC-1295.

Which safety facts matter most?

Safety fact one: CJC-1295 isn't approved for people anywhere. No large or long safety study exists. The people tests were brief and small [1] [17]. Your risk over many years remains unknown.

Safety fact 2: the CJC-1295 tests stopped after Phase 2. That phase is an early test with more people. A patient died during that period, but public sources don't show that CJC-1295 caused the death [7]. The public account also gives no clear reason for the stop.

Safety fact three: DAC and no-DAC get mixed together. No-DAC is the form that clears sooner. DAC, the part that joins a blood protein, can keep the drug in blood for days [2] [16]. Knowing the form changes how you read a report.

Safety fact 4: higher IGF-1 raises a cancer concern. CJC-1295 raises growth hormone and the blood protein IGF-1. A broad review linked higher IGF-1 with modestly higher risks for certain cancers [18]. This page lacks a cancer-by-cancer count or the size of each rise. The review therefore raises concern but can't forecast your risk.

Safety fact five: growth hormone tells the kidneys to retain fluid. The kidneys may keep extra salt and water. That can help explain swelling. Fluid pressing on a nerve may also explain tingling [19].

Safety fact 6: growth hormone may also raise blood sugar. Insulin moves sugar from your blood into the body. In one related-drug study, insulin did that task less well [10]. Poorer insulin action can leave more sugar in blood.

Safety fact seven: the FDA raised concern about an immune response. Your body might treat this peptide, or short protein chain, as something to fight. The federal list names bulk ingredients that some pharmacies may make into medicine for one patient. CJC-1295 was not added to that list [20] [12]. That refusal isn't proof that every person would be harmed.

Safety fact 8: sports officials ban CJC-1295 at all times. The World Anti-Doping Agency makes rules for tested sports. Its ban matters to athletes in those events. Tests can find the drug [21].